Brief: Innate Pharma: Hart-Scott-Rodino Clearance Regarding Expansion Of Collaboration With Sanofi On NK Cell Engagers
Jan 25 (Reuters) - Innate Pharma SA IPH.PA :
* ANNOUNCES HART-SCOTT-RODINO CLEARANCE REGARDING EXPANSION
OF ITS
COLLABORATION WITH SANOFI ON NK CELL ENGAGERS
* ANNOUNCED TODAY EXPIRATION OF WAITING PERIOD UNDER
HART-SCOTT-RODINO (HART-SCOTT-RODINO) ANTITRUST IMPROVEMENTS ACT
OF 1976 WITH RESPECT TO PREVIOUSLY ANNOUNCED EXPANSION OF ITS
COLLABORATION WITH SANOFI
* LICENSING AGREEMENT IS NOW EFFECTIVE.
Source text for Eikon: ID:nBw2tSTs6a
Further company coverage: IPH.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Innate Pharma SA
See all newsBrief: Innate Pharma Announces Completion Of Enrollment In Phase 1 Dose Escalation Study Of Iph4502
France's Innate Pharma posts lower 2025 revenue as key contracts decline
Brief: Innate Pharma FY Operating Expenses EUR -63.013 Million
Brief: Innate Pharma Sa Says Sanofi to invest up to 15 million Euros In Innate Pharma
Brief: Innate Pharma Says Jonathan Dickinson To Be Appointed CEO And Board Member